SIGILON THERAPEUTICS INC (SGTX) Stock Income Statement
NASDAQ:SGTX - Nasdaq - US82657L2060 - Common Stock - Currency: USD
| TTM (2023-3-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.64M | 12.94M | 9.60M | 13.37M | 14.16M | |||
| Operating Expenses | 52.07M | 56.61M | 85.23M | 66.02M | 58.28M | |||
| Research and Development | 33.80M | 37.63M | 65.07M | 53.49M | 48.11M | |||
| Selling, General, and Administrative Expenses | 18.28M | 18.98M | 20.17M | 12.53M | 10.17M | |||
| Operating Income | -37.44M | -43.67M | -75.64M | -52.64M | -44.12M | |||
| Interest Income/Expense | -1.05M | -1.34M | -1.73M | -890.00K | 410.00K | |||
| Other Income/Expense | 1.41M | 1.45M | 55.00K | -733.00K | -210.00K | |||
| Non Recurring Items | N/A | N/A | 0.00 | -343.00K | 0.00 | |||
| Income Before Taxes | -37.08M | -43.56M | -77.31M | -54.61M | -43.93M | |||
| Net Income | -37.08M | -43.56M | -77.31M | -54.61M | -43.93M | |||
| EBITDA | -36.17M | -42.40M | -74.52M | -51.79M | -43.44M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -9.55 | -17.48 | -31.55 | -22.56 | -1.53 | |||
| Non GAAP EPS | -9.67 | -7.11 | -2.43 | N/A | N/A | |||
| Statistics | ||||||||
| Profit Margin | -253.33% | -336.53% | -805.41% | -408.31% | -310.24% | |||
| Operating Profit Margin | -255.76% | -337.35% | -787.96% | -393.61% | -311.58% | |||
All data in USD